Long-term management of immunosuppression after pediatric liver transplantation: Is minimization or withdrawal desirable or possible or both?

Current Opinion in Organ Transplantation

Volumn 13, Issue 5, 2008, Pages 506-512

  Feng, Sandy ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Immunosuppression; Outcomes; Pediatric liver transplantation; Tolerance

Indexed keywords

ALEMTUZUMAB; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; AZATHIOPRINE; BIOLOGICAL MARKER; CALCINEURIN INHIBITOR; CORTICOSTEROID; CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; TACROLIMUS; THYMOCYTE ANTIBODY;

CARDIOVASCULAR RISK; CAUSE OF DEATH; CHRONIC DISEASE; CHRONIC GRAFT REJECTION; CLINICAL TRIAL; DIABETES MELLITUS; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; EXPERIENCE; GRAFT FAILURE; GRAFT RECIPIENT; GRAFT REJECTION; GRAFT SURVIVAL; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; KIDNEY DISEASE; LIVER TRANSPLANTATION; LONG TERM CARE; LUNG GRAFT REJECTION; LYMPHOPROLIFERATIVE DISEASE; MELANOMA; REVIEW; RISK FACTOR; SKIN CANCER; SQUAMOUS CELL CARCINOMA; WELLBEING; CARDIOVASCULAR DISEASE; CHEMICALLY INDUCED DISORDER; CHILD; DRUG ADMINISTRATION; DRUG EFFECT; IMMUNOLOGY; NEOPLASM; RISK ASSESSMENT; SURVIVOR; TIME; TREATMENT OUTCOME;

CARDIOVASCULAR DISEASES; CHILD; CHRONIC DISEASE; DRUG ADMINISTRATION SCHEDULE; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY DISEASES; LIVER TRANSPLANTATION; NEOPLASMS; RISK ASSESSMENT; SURVIVORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 60849104845     PISSN: 10872418     EISSN: 15317013     Source Type: Journal    
DOI: 10.1097/MOT.0b013e328310b0f7     Document Type: Review

References (52)

1. McDiarmid SV. Current status of liver transplantation in children. Pediatr Clin North Am 2003; 50:1335-1374.
2. Ryckman FC, Bucuvalas JC, Nathan J, et al. Outcomes following liver transplantation. Semin Pediatr Surg 2008; 17:123-130.
3. Magee JC, Krishnan SM, Benfield MR, et al. Pediatric transplantation in the United States, 1997-2006. Am J Transplant 2008; 8:935-945.
4. Soltys KA, Mazariegos GV, Squires RH, et al. Late graft loss or death in pediatric liver transplantation: an analysis of the SPLIT database. Am J Transplant 2007; 7:2165-2171.
5. Shepherd RW, Turmelle Y, Nadler M, et al. Risk factors for rejection and infection in pediatric liver transplantation. Am J Transplant 2008; 8:396-403.
6. Ojo AO, Held PJ, Port FK, et al. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med 2003; 349:931-940.
7. Berg UB, Ericzon BG, Nemeth A. Renal function before and long after liver transplantation in children. Transplantation 2001; 72:631-637.
8. Alonso EM. Long-term renal function in pediatric liver and heart recipients. Pediatr Transplant 2004; 8:381-385.
9. Avitzur Y, De Luca E, Cantos M, et al. Health status ten years after pediatric liver transplantation - looking beyond the graft. Transplantation 2004; 78:566-573.
10. Mention K, Lahoche-Manucci A, Bonnevalle M, et al. Renal function outcome in pediatric liver transplant recipients. Pediatr Transplant 2005; 9:201-207.
11. Campbell KM, Yazigi N, Ryckman FC, et al. High prevalence of renal dysfunction in long-term survivors after pediatric liver transplantation. J Pediatr 2006; 148:475-480.
12. Hogg RJ, Furth S, Lemley KV, et al. National Kidney Foundation's Kidney Disease Outcomes Quality Initiative clinical practice guidelines for chronic kidney disease in children and adolescents: evaluation, classification, and stratification. Pediatrics 2003; 111:1416-1421.
13. Bartosh SM, Alonso EM, Whitington PF. Renal outcomes in pediatric liver transplantation. Clin Transplant 1997; 11:354-360.
14. Del Compare ME, D'Agostino D, Ferraris JR, et al. Twenty-four-hour ambulatory blood pressure profiles in liver transplant recipients. Pediatr Transplant 2004; 8:496-501.
15. Wallot MA, Mathot M, Janssen M, et al. Long-term survival and late graft loss in pediatric liver transplant recipients - a 15-year single-center experience. Liver Transplant 2002; 8:615-622.
16. Fridell JA, Jain A, Reyes J, et al. Causes of mortality beyond 1 year after primary pediatric liver transplant under tacrolimus. Transplantation 2002; 74:1721-1724.
17. Migliazza L, Lopez Santamaria M, Murcia J, et al. Long-term survival expectancy after liver transplantation in children. J Pediatr Surg 2000; 35:5-7. [discussion 7-8].
18. Otley CC, Pittelkow MR. Skin cancer in liver transplant recipients. Liver Transplant 2000; 6:253-262.
19. Euvrard S, Kanitakis J, Cochat P, Claudy A. Skin cancers following pediatric organ transplantation. Dermatol Surg 2004; 30:616-621.
20. SPLIT Research Group. SPLIT Annual Report 2006. Rockville, Maryland; 2006.
21. Horslen S, Barr ML, Christensen LL, et al. Pediatric transplantation in the United States, 1996-2005. Am J Transplant 2007; 7:1339-1358.
22. Eason JD, Loss GE, Blazek J, et al. Steroid-free liver transplantation using rabbit antithymocyte globulin induction: results of a prospective randomized trial. Liver Transplant 2001; 7:693-697.
23. Tzakis AG, Tryphonopoulos P, Kato T, et al. Preliminary experience with alemtuzumab (Campath-1H) and low-dose tacrolimus immunosuppression in adult liver transplantation. Transplantation 2004; 77:1209-1214.
24. Tryphonopoulos P, Tzakis AG, Weppler D, et al. The role of donor bone marrow infusions in withdrawal of immunosuppression in adult liver allotransplantation. Am J Transplant 2005; 5:608-613.
25. Marcos A, Eghtesad B, Fung JJ, et al. Use of alemtuzumab and tacrolimus monotherapy for cadaveric liver transplantation: with particular reference to hepatitis C virus. Transplantation 2004; 78:966-971.
26. Eghtesad B, Fung JJ, Demetris AJ, et al. Immunosuppression for liver transplantation in HCV-infected patients: mechanism-based principles. Liver Transplant 2005; 11:1343-1352.
27. Eason JD, Cohen AJ, Nair S, et al. Tolerance: is it worth the risk? Transplantation 2005; 79:1157-1159.
28. Calne RY, Sells RA, Pena JR, et al. Induction of immunological tolerance by porcine liver allografts. Nature 1969; 223:472-476.
29. Starzl TE, Marchioro TL, Porter KA, et al. Factors determining short- and longterm survival after orthotopic liver homotransplantation in the dog. Surgery 1965; 58:131-155.
30. Kamada N, Davies HS, Roser B. Reversal of transplantation immunity by liver grafting. Nature 1981; 292:840-842.
31. Qian S, Demetris AJ, Murase N, et al. Murine liver allograft transplantation: tolerance and donor cell chimerism. Hepatology 1994; 19:916-924.
32. Neuberger J, Adams DH. What is the significance of acute liver allograft rejection? J Hepatol 1998; 29:143-150.
33. Wiesner RH, Demetris AJ, Belle SH, et al. Acute hepatic allograft rejection: incidence, risk factors, and impact on outcome. Hepatology 1998; 28:638-645.
34. Klompmaker LJ, Gouw AS, Haagsma EB, et al. Selective treatment of early acute rejection after liver transplantation: effects on liver, infection rate, and outcome. Transpl Int 1997; 10:40-44.
35. Dousset B, Hubscher SG, Padbury RT, et al. Acute liver allograft rejection - is treatment always necessary? Transplantation 1993; 55:529-534.
36. Libby P, Pober JS. Chronic rejection. Immunity 2001; 14:387-397.
37. Jain A, Mazariegos G, Pokharna R, et al. Almost total absence of chronic rejection in primary pediatric liver transplantation under tacrolimus. Transplant Proc 2002; 34:1968-1969.
38. Cao S, Cox KL, Berquist W, et al. Long-term outcomes in pediatric liver recipients: comparison between cyclosporin A and tacrolimus. Pediatr Transplant 1999; 3:22-26.
39. Gupta P, Hart J, Cronin D, et al. Risk factors for chronic rejection after pediatric liver transplantation. Transplantation 2001; 72:1098-1102.
40. Ramos HC, Reyes J, Abu-Elmagd K, et al. Weaning of immunosuppression in long-term liver transplant recipients. Transplantation 1995; 59:212-217.
41. Mazariegos GV, Reyes J, Marino IR, et al. Weaning of immunosuppression in liver transplant recipients. Transplantation 1997; 63:243-249.
42. Devlin J, Doherty D, Thomson L, et al. Defining the outcome of immunosuppression withdrawal after liver transplantation. Hepatology 1998; 27:926-933.
43. Takatsuki M, Uemoto S, Inomata Y, et al. Weaning of immunosuppression in living donor liver transplant recipients. Transplantation 2001; 72:449-454.
44. Oike F, Yokoi A, Nishimura E, et al. Complete withdrawal of immunosuppression in living donor liver transplantation. Transplant Proc 2002; 34:1521.
45. Pons JA, Yelamos J, Ramirez P, et al. Endothelial cell chimerism does not influence allograft tolerance in liver transplant patients after withdrawal of immunosuppression. Transplantation 2003; 75:1045-1047.
46. Girlanda R, Rela M, Williams R, et al. Long-term outcome of immunosuppression withdrawal after liver transplantation. Transplant Proc 2005; 37:1708-1709.
47. Tisone G, Orlando G, Cardillo A, et al. Complete weaning off immunosuppression in HCV liver transplant recipients is feasible and favourably impacts on the progression of disease recurrence. J Hepatol 2006; 44:702-709.
48. Assy N, Adams PC, Myers P, et al. Randomized controlled trial of total immunosuppression withdrawal in liver transplant recipients: role of ursodeoxycholic acid. Transplantation 2007; 83:1571-1576.
49. Koshiba T, Li Y, Takemura M, et al. Clinical, immunological, and pathological aspects of operational tolerance after pediatric living-donor liver transplantation. Transpl Immunol 2007; 17:94-97.
50. Lerut J, Sanchez-Fueyo A. An appraisal of tolerance in liver transplantation. Am J Transplant 2006; 6:1774-1780.
51. Mazariegos GV, Sindhi R, Thomson AW, Marcos A. Clinical tolerance following liver transplantation: long term results and future prospects. Transpl Immunol 2007; 17:114-119.
52. Martinez-Llordella M, Puig-Pey I, Orlando G, et al. Multiparameter immune profiling of operational tolerance in liver transplantation. Am J Transplant 2007; 7:309-319.